Asperuloside alleviates osteoporosis by promoting autophagy and regulating Nrf2 activation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39702357.
- Also identified by DOI 10.1186/s13018-024-05320-8 and PMC identifier 11658297.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Osteoporosis is a metabolic bone disease that has a common occurrence in postmenopausal women. Asperuloside (ASP) has been reported to exert anti-inflammatory and anti-oxidative effects in numerous diseases, such as rheumatoid arthritis and acute lung injury. However, whether ASP plays a role in osteoporosis has not been addressed. In vivo, ovariectomy (OVX) was used to induce mouse osteoporosis. Then, the mice were treated with 20 and 40 mg/kg ASP. In vitro, MC3T3-E1 cells were treated with 0, 1, 10, 20, 40 and 80 µM ASP. We chose 20 and 40 µM for further experiments due to no significant effects on cell viability. The data indicated that ASP reduced osteoporosis in OVX mice and promoted osteogenic differentiation and mineralization in MC3T3-E1 cells. In addition, we explored that ASP protected against osteoporosis via inducing autophagy and activating Nrf2. ASP alleviates OVX-induced osteoporosis by promoting autophagy and regulating Nrf2 activation.
Medical subject headings
- NF-E2-Related Factor 2
- Autophagy
- Osteoporosis